Advertisement

Journal of Endocrinological Investigation

, Volume 16, Issue 9, pp 675–677 | Cite as

Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism

  • E. Faloia
  • S. Filipponi
  • V. Mancini
  • P. Morosini
  • R. De Pirro
Article

Abstract

Six women with acne and six women with hirsutism were treated with the GnRH analog [D-Ser(But)6] LHRH-(1–9)ethylamide (Buserelin®) for 6 months (nasal spray, 1,200 μg/day) to suppress ovarian steroidogenesis. All women were eumenorrheic and did not demonstrate any adrenal or ovarian dysfunction. During treatment, ovarian steroids, LH and FSH decreased, while DHEA-S showed minor modifications; the clinical score for both acne and hirsutism showed a significant reduction. Moreover, acne and hirsutism were still well controlled 6 months after therapy. Gonadal function resumed in all patients after discontinuation of therapy. Three patients suffered from hot flashes from the 4th month. These data demonstrate that suppression of ovarian steroid secretion might be an efficient treatment in women suffering from acne or idiopathic hirsutism, indicating that ovarian steroids may have a key-role in the pathogenesis of these conditions.

Key-words

Acne idiopathic hirsutism ovarian steroidogenesis GnRH analogs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Biffignandi P., Massucchetti C., Molinatti G.M. Female Hirsutism: Pathophysiological considerations and therapeutic implications. Endocri. Rev. 5: 498, 1984.CrossRefGoogle Scholar
  2. 2.
    Conn P.M., Crowley W.F.J. Gonadotropin-releasing hormone and its analogues. N.Engl. J.Med. 324: 93, 1991.PubMedCrossRefGoogle Scholar
  3. 3.
    Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21: 1440, 1961.PubMedCrossRefGoogle Scholar
  4. 4.
    Lucky A.W., McGuire J., Rosenfield R.L., Lucky P.A., Rich B.H. Plasma androgens in women with acne vulgaris. J. Invest. Dermatol. 81: 70, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    White P.C., New M.I., Dupont B. Congenital Adrenal Hyperplasia. N.Engl. J. Med. 316: 1519, 1987.PubMedCrossRefGoogle Scholar
  6. 6.
    Rittmaster R.S., Thompson D.L. Effect of Leuprolide and Dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J. Clin. Endocrinol. Metab. 70: 1096, 1990.PubMedCrossRefGoogle Scholar
  7. 7.
    Andreiko J.L., Monroe S.E., Jaffe R.B. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J. Clin. Endocrinol. Metab. 63: 854, 1986.CrossRefGoogle Scholar
  8. 8.
    Matta W.H., Shaw R.W., Hesp R., Katz D. Hypogonadism induced by luteinizing releasing hormone agonist analogue: Effects on bone density in premenopausal women. Br. Med. J. 294: 1523, 1987.CrossRefGoogle Scholar
  9. 9.
    Johansen J.S., Riis B.J., Hassager C., Moen M., Jacobson J., Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocrinol. Metab. 67: 701, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Riis B.J., Christiansen C., Johansen J.S., Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J. Clin. Endocrinol. Metab. 70: 920, 1990.PubMedCrossRefGoogle Scholar
  11. 11.
    Surrey E.S., Judd H.L Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting Gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J. Clin. Endocrinol. Metab. 75: 558, 1992.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1993

Authors and Affiliations

  • E. Faloia
    • 1
  • S. Filipponi
    • 1
  • V. Mancini
    • 1
  • P. Morosini
    • 1
  • R. De Pirro
    • 1
  1. 1.Clinica di Endocrinologia, Ospedale Regionale TorretteUniversità di AnconaAnconaItaly

Personalised recommendations